From Scottish Medicines Consortium 9 September 2019
Dapagliflozin has been accepted for the treatment of inadequately controlled type one diabetes mellitus as an adjunct to insulin if their body mass index is at or above 27.
The combination significantly improves glycaemic control.
My comment: In my experience the combination is also good for weight control. These findings have been known for several years from USA research so it is good that Scottish doctors are being encouraged in its use.